A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
Press releases
Vivos Inc. Certifies New Clinic for IsoPet Therapy.
NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, NJ
provides 24/7/365 emergency, trauma, and critical care and a suite of veterinary specialty services for small animals. They have been approved and licensed to offer IsoPet Precision Radionuclide Therapy as a cancer treatment for small animals.
Dr. Korenko stated “An important objective is to expand the number of clinics that are certified
for IsoPet Therapy. Generally, different clinics specialize in small animal or equine therapy.
Certification is much lower cost than other alternatives that require large capital investments. It
requires veterinarians and oncologists that are enthusiastic about the effectiveness of IsoPet.
Vivos assists them with obtaining or amending their radioactive material license and provides
the certification training that includes our proprietary Injection Guidance Table. We now have
several clinics in the pipeline.”
Michael K. Korenko, Sc.D.
President & CEO Vivos Inc
Email: MKorenko@RadioGel.com
Follow Vivos Inc @VivosIncUSA, RadioGel ® and IsoPet ® on X (Twitter):
September 30, 2024
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc.
We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals.
Dr. Korenko commented, “While we have experience treating cats, dogs, and horses, there is a growing need to address cancer treatment for other pets and zoo animals. We have been attending relevant conferences to raise awareness about using IsoPet Precision Radionuclide Therapy as an innovative cancer treatment for solid cancerous tumors in all animals.”
Michael K. Korenko, Sc.D.
President & CEO Vivos Inc
Press Releases
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
August 07, 2023
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT).
The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire, the Hopkinton Animal Hospital, located in Weare, New Hampshire and the Indian Creek Veterinary Hospital, located in Fort Wayne, Indiana.
Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
January 02, 2018